Evidence map›Paper›PMID 41423942›Full record

ArticleThe American journal of case reports2025

Afebrile Recurrent Cellulitis Complicated by Linezolid-Induced Lactic Acidosis in an Elderly Patient.

Yanizbeth Yambó-Chévere, Rafael Bermúdez-Rivera

Abstract readCase Reports
In one paragraph

Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yanizbeth Yambó-ChévereDepartment of Medicine, Ponce Health Sciences University, Ponce, Puerto Rico.
Rafael Bermúdez-RiveraDepartment of Medicine, Ponce Health Sciences University, Ponce, Puerto Rico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Cellulitis typically presents with erythema, swelling, warmth, and systemic signs such as fever and leukocytosis. In older adults, immunosenescence and multimorbidity can blunt classical inflammatory responses, delaying diagnosis and complicating care. Linezolid, while effective against resistant gram-positive organisms, carries a risk of mitochondrial dysfunction and lactic acidosis during prolonged therapy. CASE REPORT We describe the case of an 87-year-old Puerto Rican woman with multiple comorbidities who experienced 4 hospitalizations in 6 months for recurrent cellulitis. Despite having visible inflammation, she consistently remained afebrile and without leukocytosis. Laboratory findings demonstrated a persistently elevated C-reactive protein level and erythrocyte sedimentation rate. Wound cultures revealed polymicrobial organisms, including Pseudomonas aeruginosa, Klebsiella pneumoniae, and Stenotrophomonas maltophilia. Broad-spectrum antibiotics were used, including linezolid at 600 mg twice daily, with an estimated total exposure of approximately 8 weeks across hospitalizations and outpatient treatment. Renal and hepatic function were monitored and remained stable throughout. Ultrasound imaging did not reveal abscess or osteomyelitis. During the final hospitalization, she developed lactic acidosis (lactate 2.5-3.1 mmol/L), in the absence of shock or hypoxemia, suggesting linezolid-induced mitochondrial toxicity. The patient died 2 days after discharge. CONCLUSIONS This case underscores the diagnostic challenges of afebrile cellulitis in frail older adults and the importance of careful antimicrobial stewardship. Clinicians should maintain vigilance for linezolid-induced lactic acidosis during extended therapy, particularly in patients with atypical presentations. The integration of biomarker trends into decision-making, prioritization of preventive strategies, and coordination of geriatric care are essential to improve outcomes in this vulnerable population.

Indexed as

Acidosis, LacticAnti-Bacterial AgentsCellulitisLinezolidAged, 80 and overFemaleHumansRecurrenceAnti-Bacterial AgentsLinezolid

Identifiers

PMID41423942
PMCPMC12777370

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.